Table 2 Patients’ characteristics
n = 32 (%) | |
|---|---|
Age | |
Median-years (range) | 66 (50–76) |
≥ 65 | 18 (56) |
Sex | |
Female | 17 (53) |
Male | 15 (47) |
Ethnicity | |
Caucasian | 19 (59) |
African–American | 12 (38) |
Hispanic | 1 (3) |
ECOG performance status | |
0 | 6 (19) |
1 | 25 (78) |
2 | 1 (3) |
MM subtype | |
IgG | 13 (41) |
IgA | 8 (25) |
Light chain | 9 (28) |
Missing | 2 (6) |
International staging system | |
I | 18 (56) |
II | 3 (9) |
III | 9 (28) |
Missing | 2 (6) |
Bone marrow infiltration | |
Plasma cells, % median (range) | 30 (1–90) |
Prior lines of therapy, number | |
Median, range | 4 (1–8) |
Prior Bortezomib | 29 (91) |
- refractory | 17 (53) |
Prior Lenalidomide | 29 (91) |
- refractory | 10 (31) |
Prior pomalidomide | 7 (22) |
Prior anti-CD38 | 4 (13) |
Prior autologous stem cell transplantation | 30 (94) |
Disease status at study entry | |
Relapse and refractory | 27 (84) |
Relapse | 5 (16) |
